Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

Treatment Updates in Early Stage NSCLC - Advances in Thoracic Oncolo…

Total Health

J. Porter

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu

WCLC 2024 Summary: Comparing Treatment for Locally Advanced NSCLC - …

Insights from 2024 WCLC

J. Donington

How the Experts Treat: Early Stage NSCLC With Curative Intent

Integrity CE

S. Liu

ADC in Combination With Immunotherapy for NSCLC

MI&T Congressi

S. Liu

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

Current & Future Directions of IO in Early Stage NSCLC

Federico Cappuzzo

Neoadjuvant Chemoimmunotherapy in Unresectable NSCLC

MI&T Congressi

I. Opitz

New Immune Checkpoint Inhibitors in Lung Cancer

MI&T Congressi

S. Peters

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

How the Experts Treat: Adjuvant or Neoadjuvant Immunotherapy for NSC…

MI&T Congressi

T. Cascone

Neoadjuvant and Adjuvant Therapies in NSCLC: Are We Saving Lives?

MI&T Congressi

G. Scagliotti